Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Fabry disease

Effects of agalsidase-β shortage in Fabry disease

Nature Reviews Nephrology volume 11, page 566 (2015)Cite this article

Subjects

A shortage in agalsidase-β between 2009 and 2012 resulted in patients with Fabry disease either receiving reduced doses or switching to agalsidase-α. Lenders et al. found that patients who reduced doses or switched medications exhibited a decline in renal function compared to those who received the standard agalsidase-β treatment regimen. All patients, however, showed a stable clinical disease course.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Lenders, M. et al. Patients with Fabry disease after enzyme replacement therapy dose reduction and switch-2-year follow-up. J. Am. Soc. Nephrol. 10.1681/ASN.2015030337

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Effects of agalsidase-β shortage in Fabry disease. Nat Rev Nephrol 11, 566 (2015). https://doi.org/10.1038/nrneph.2015.139

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrneph.2015.139

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing